Dr. Corey Siegel

Gastroenterologist · Lebanon, New Hampshire
  • 2 Emerging Treatments
  • 120 Publications

Dr. Corey Siegel is the Section Chief of Gastroenterology and Hepatology and the Co-Director of the Inflammatory Bowel Disease (IBD) Center at the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire. He is also an Associate Professor of Medicine at the Geisel School of Medicine at Dartmouth.

With a primary focus on the care of patients with inflammatory bowel disease (IBD) including Crohn's Disease and Ulcerative Colitis, Dr. Siegel performs clinical trials for new therapies for IBD, and also has expertise in colonoscopy and upper endoscopy. Dr. Siegel is known for his personalized patient care and proactive approach to treatment.

One of the most important new advances in Crohn's disease treatment is the concept of 'early intensive therapy.' We've learned through research that if we treat people earlier on with our most effective drugs or combinations of drugs, it increases our chances of making them better.
- Dr. Corey Siegel, 2018


Experience

Co-Chair

IBD Qorus · 2016 - Present

Qorussmall

IBD Qorus is the Crohn's & Colitis Foundation's national initiative to improve the quality of care delivered to patients with Crohn's disease and ulcerative colitis, also known as inflammatory bowel diseases (IBD). The expanding program is creating a collaborative Learning Health System that empowers healthcare providers to share ideas and report quality metrics to a common platform, enabling researchers to compare patient experiences and treatment outcomes over time and across a variety of care settings. The studies made possible by IBD Qorus will lead to discoveries and insights to enhance health outcomes, as well as quality of life, for IBD patients.

Co-Founder

BRIDGe Group · 2005 - Present

Bridge group

The BRIDGe group is a collaboration of 13 gastroenterologists with expertise in inflammatory bowel disease (IBD). BRIDGe was formed in 2005 and is composed of a group of gastroenterologists who are all experts in IBD-patient care and focused on patient-centered clinical IBD research. We have a broad array of research skills, and collectively our medical centers, which span four countries on three continents, follow over 10,000 patients with IBD. Since forming in 2005 we have taken on challenging collaborative clinical research projects to help drive the future of IBD care.

Associate Professor of Medicine

The Dartmouth Institute for Health Policy · 2005 - Present

The dartmouth institute for health policy and clinical practice   white

The Dartmouth Institute for Health Policy and Clinical Practice (TDI) is an organization within Dartmouth College "dedicated to improving health care through education, research, policy reform, leadership improvement, and communication with patients and the public."

Co-Director of the Inflammatory Bowel Disease (IBD) Center

Dartmouth-Hitchcock Medical Center · 2005 - Present

Dartmouth hitchcock medical center long

Dartmouth-Hitchcock (D-H) is a nonprofit academic health system serving communities in northern New England. D-H provides access to more than 1,000 primary care doctors and specialists in almost every area of medicine at Dartmouth-Hitchcock Medical Center. The Dartmouth-Hitchcock IBD Center cares for approximately 2000 patients with IBD.


Education

Graduate

The Dartmouth Institute for Health Policy

The dartmouth institute for health policy and clinical practice   white

Fellowship, Inflammatory Bowel Disease

Massachusetts General Hospital · 2004 - 2005

Massachusetts general hospital

Fellowship, Gastroenterology

Dartmouth-Hitchcock Medical Center · 2002 - 2005

Dartmouth hitchcock medical center long

Residency, Internal Medicine

Dartmouth-Hitchcock Medical Center · 1998 - 2002

Dartmouth hitchcock medical center long


Publications

Dr. Corey Siegel has been involved in 120 publications. View publications ›


Locations

Dr. Corey Siegel is affiliated with Dartmouth-Hitchcock Medical Center at 1 Medical Center Dr, Lebanon, NH 03756.

Get Involved

Answer a few questions to see if this new treatment is right for you.

Join Now